IL 1512
Alternative Names: IL-1512Latest Information Update: 12 Aug 2024
At a glance
- Originator iLeadBMS
- Class Antifibrotics; Small molecules
- Mechanism of Action CXCR7 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis
Most Recent Events
- 05 Jun 2024 Pharmacodynamics data from a preclinical studies in Idiopathic pulmonary fibrosis presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)
- 17 May 2024 Preclinical trials in Idiopathic pulmonary fibrosis in South Korea (PO), prior to June 2024
- 17 May 2024 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Idiopathic pulmonary fibrosis presented at the 120th International Conference of the American Thoracic Society (ATS-2024)